158 related articles for article (PubMed ID: 26241546)
1. Prognostic significance of DLL4 expression in papillary thyroid cancer.
Zhang YZ; Qin F; Han ZG; Liu Q; Zhou L; Wang YW
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(15):2901-5. PubMed ID: 26241546
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
3. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
[TBL] [Abstract][Full Text] [Related]
4. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
[TBL] [Abstract][Full Text] [Related]
5. Delta-like 4/Notch pathway is differentially regulated in benign and malignant thyroid tissues.
Geers C; Colin IM; Gérard AC
Thyroid; 2011 Dec; 21(12):1323-30. PubMed ID: 22066479
[TBL] [Abstract][Full Text] [Related]
6. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
7. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
8. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma.
Kong L; Zhang G; Wang X; Zhou J; Hou S; Cui W
Rom J Morphol Embryol; 2013; 54(3):499-503. PubMed ID: 24068396
[TBL] [Abstract][Full Text] [Related]
11. Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review.
Chruścik A; Lam AK
Exp Mol Pathol; 2015 Dec; 99(3):393-8. PubMed ID: 26321247
[TBL] [Abstract][Full Text] [Related]
12. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
13. DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer.
Yang S; Liu Y; Xia B; Deng J; Liu T; Li Q; Yang Y; Wang Y; Ning X; Zhang Y; Xiao M
Tumour Biol; 2016 Apr; 37(4):5063-74. PubMed ID: 26546434
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
[TBL] [Abstract][Full Text] [Related]
15. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
18. Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region.
Kaliszewski K; Diakowska D; Strutynska-Karpinska M; Rzeszutko M; Grzegrzolka J; Dziegiel P; Wojtczak B; Sutkowski K
Folia Histochem Cytobiol; 2016; 54(4):193-201. PubMed ID: 28051274
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
20. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Wang JR; Li XH; Gao XJ; An SC; Liu H; Liang J; Zhang K; Liu Z; Wang J; Chen Z; Sun W
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):427-35. PubMed ID: 23467939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]